As Kidney International Reports® (KIR) marks its tenth anniversary, Editor-in-Chief Jai Radhakrishnan reflects on the trust, teamwork, and willingness to innovate that have shaped the journal from its earliest days. "KIR belongs to the community," he says, "When the journal was new, and its future uncertain, authors and reviewers placed their confidence in it. Their...
Kidney International® Kidney stone disease – to drink or not to drink, that is the question Increasing fluid intake is widely recommended to prevent kidney stone recurrence, but many patients struggle to maintain adequate hydration. This editorial examines the PUSH trial, which tested interventions to increase fluid intake and achieve the recommended urine output of 2.5 liters...
Kidney International® A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease Somatostatin analogues can reduce cyst volume in autosomal dominant polycystic kidney disease (ADPKD), but their effect on kidney function remains uncertain. This three-year randomized, placebo-controlled trial tested whether lanreotide could slow kidney function decline in adults with stage 2/3...
Vivekanand Jha named editor-in-chief of Kidney International Reports® October 21, 2026 The International Society of Nephrology (ISN) is pleased to announce the appointment of Vivekanand Jha as the next editor-in-chief of Kidney International Reports® (KIR), an official ISN open-access journal. His term will begin on January 1, 2027, succeeding Jai Radhakrishnan, who has been appointed next...
Kidney International® New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes Dapagliflozin improves kidney outcomes in chronic kidney disease (CKD), but the mechanisms behind these benefits are not fully understood. This DAPA-CKD proteomic analysis found that dapagliflozin modifies biological pathways linked to CKD progression, particularly those involving inflammation, fibrosis, and tissue remodeling. The...
Kidney International® Real-world outcomes of pegcetacoplan in primary membranoproliferative glomerulonephritis Pegcetacoplan is being explored as a treatment for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, but real-world evidence remains limited. This observational study followed 25 pediatric and adult patients treated outside clinical trials, most of whom had not responded to conventional therapies. Pegcetacoplan was associated with rapid...
Kidney International® Respiratory syncytial virus vaccination induces delayed but robust humoral and cellular immunity in patients receiving hemodialysis Patients receiving hemodialysis are especially vulnerable to respiratory syncytial virus (RSV), but vaccine responses in this group are poorly understood. In a small observational study, the RSV vaccine Arexvy produced robust antibody and cellular immune responses, although antibody levels rose more slowly than...
Jai Radhakrishnan (left) and Sumit Mohan What does kidney research publishing look like in a rapidly evolving field? As Kidney International Reports® (KIR) marks its 10th anniversary, its editors discuss how the journal is expanding engagement with the global kidney community, adapting to new developments in publishing, and looking ahead to its next...
Kidney International® Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background C3 glomerulopathy (C3G) has a high risk of recurrence after kidney transplantation, and there is limited evidence on how best to prevent it. This case report describes a child with severe, early-onset C3G and a complex genetic background who received pegcetacoplan before and after a living-donor kidney transplant as prophylaxis...
Kidney International® Reversal of advanced diabetic kidney disease in mice achieved with a monoclonal anti-VEGFR1 antibody Diabetic kidney disease is a major cause of kidney failure, and new treatment approaches are needed. In this study, researchers tested various strategies to target the VEGF-A pathway in mouse models of diabetic kidney disease and chronic kidney disease. They found that...
Kidney International® Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis Lupus nephritis is complex and difficult to treat, and clinicians need better tools to understand which patients are most likely to benefit from specific therapies. Using data from the Phase 3 BLISS-LN study, researchers assessed how belimumab affected immune...
The ISN invites applications for editor-in-chief (EIC) of Kidney International Reports®. The EIC will shape the journal’s editorial direction and support the publication of high-quality, clinically relevant kidney research for a global audience. Applications close on July 31, 2026. View the role, criteria, and how to apply
Kidney International® A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy This study tested whether lower-dose prednisolone combined with activated vitamin D could match standard high-dose prednisolone for remission in adults with minimal change disease while reducing steroid toxicity. Although non-inferiority was not formally established, the lower-dose regimen...
The ISN invites applications for editor-in-chief of Kidney International Reports® (KIR). The successful candidate will serve a five-year term (January 2, 2027–December 31, 2031). Applications close on July 31, 2026. Please refer to ISN’s equity, diversity, and inclusion statement. Read the full job description and apply
Kidney International® Conventional cytotoxic chemotherapy–associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) Workgroup Conventional cytotoxic chemotherapy remains essential in cancer care, but can cause acute and chronic kidney injury. The 34th ADQI Workgroup reviewed the epidemiology, mechanisms, risk factors, clinical manifestations, prevention, and management of nephrotoxicity linked to commonly used agents. The resulting consensus report emphasizes clinician awareness,...
“We are truly a global journal: We do not just select [from] one area that has resources ... authors can submit their papers from whatever region they’re from.” Jai Radhakrishnan As Kidney International Reports® (KIR) marks its 10th anniversary, a WCN'26 Kidney Studio interview with Editor-in-Chief Jai Radhakrishnan reflects on how a bold early commitment to open access and a dedication to...
A new case report in Kidney International Case Reports™ (KICR) describes an exceptionally rare delayed dual invasive fungal infection involving mucormycosis and aspergillosis in the native kidney of a kidney transplant recipient more than 10 years after transplantation. Macroscopic appearance of small whitish tissue (fungal ball) passed in urine The patient presented with fever, right loin...
Kidney International® A population-based,regression discontinuity analysis examined the effects of nationwide alerting for acute kidney injury on health care and patient outcomes This study assessed whether Wales’ nationwide electronic alerts for acute kidney injury (AKI) improved care or patient outcomes in real-world practice. Using a population-based regression discontinuity analysis of hospital and community data from 2016 to...
Kidney International® Tiny warriors, big impact: targeted immunotherapy in kidney diseases This review examines whether emerging B cell-targeting immunotherapies, particularly chimeric antigen receptor T-cell therapy and T-cell engagers, could improve outcomes in autoimmune kidney diseases where current treatments often fail. It summarizes early evidence, mainly from small uncontrolled studies in systemic lupus erythematosus, suggesting these approaches may achieve deeper B-cell depletion...
Jai Radhakrishnan named Editor-in-Chief of Kidney International® May 7, 2026 The International Society of Nephrology (ISN) is pleased to announce the appointment of Jai Radhakrishnan, MD, as the next Editor-in-Chief of Kidney International® (KI), the Society’s flagship journal. His term will begin on January 1, 2027, succeeding Pierre Ronco, MD, PhD. Dr. Radhakrishnan is a Professor of...
